• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Financial Officer Miller Steven Clive converted options into 28,475 shares and covered exercise/tax liability with 15,752 shares, increasing direct ownership by 6% to 233,123 units (SEC Form 4)

    9/5/25 5:12:43 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care
    Get the next $WRBY alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Miller Steven Clive

    (Last) (First) (Middle)
    C/O WARBY PARKER INC.,
    233 SPRING STREET, 6TH FLOOR EAST

    (Street)
    NEW YORK NY 10013

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Warby Parker Inc. [ WRBY ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    09/03/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 09/03/2025 M 28,475 A $0 248,875 D
    Class A Common Stock 09/03/2025 F(1) 15,752 D $25.55 233,123 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (2) 09/03/2025 M 3,398(3) (4) (4) Class A Common Stock 3,398 $0 0 D
    Restricted Stock Units (2) 09/03/2025 M 8,879(3) (5) (5) Class A Common Stock 8,879 $0 50,319 D
    Restricted Stock Units (2) 09/03/2025 M 10,554(3) (6) (6) Class A Common Stock 10,554 $0 102,026 D
    Restricted Stock Units (2) 09/03/2025 M 5,644(3) (7) (7) Class A Common Stock 5,644 $0 77,134 D
    Explanation of Responses:
    1. Represents shares of Class A Common Stock withheld by the Issuer to cover required tax withholding obligations in connection with the vesting of RSUs.
    2. Each RSU represents a contingent right to receive one share of the Company's Class A Common Stock.
    3. This filing relates to the occurrence of a RSU vesting event.
    4. The RSUs will vest in 48 monthly installments beginning on July 1, 2021.
    5. The RSUs will vest in 48 substantially equal monthly installments beginning on February 3, 2023.
    6. The RSUs will vest in 48 substantially equal monthly installments beginning on January 1, 2024.
    7. The RSUs will vest in 48 substantially equal monthly installments beginning on January 1, 2025.
    /s/ Chris Utecht, Attorney-in-Fact 09/05/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $WRBY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WRBY

    DatePrice TargetRatingAnalyst
    8/1/2025$22.00 → $28.00Outperform
    Telsey Advisory Group
    7/10/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    4/30/2025$17.00Sell → Neutral
    Citigroup
    4/17/2025$27.00Hold → Buy
    Loop Capital
    2/28/2025$28.00 → $30.00Outperform
    Telsey Advisory Group
    2/25/2025$26.00Neutral
    ROTH MKM
    2/5/2025$19.00 → $23.00Neutral → Sell
    Citigroup
    1/17/2025$23.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $WRBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Telsey Advisory Group reiterated coverage on Warby Parker with a new price target

    Telsey Advisory Group reiterated coverage of Warby Parker with a rating of Outperform and set a new price target of $28.00 from $22.00 previously

    8/1/25 8:16:04 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker downgraded by Citizens JMP

    Citizens JMP downgraded Warby Parker from Mkt Outperform to Mkt Perform

    7/10/25 8:37:20 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker upgraded by Citigroup with a new price target

    Citigroup upgraded Warby Parker from Sell to Neutral and set a new price target of $17.00

    4/30/25 1:18:55 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Monumental Sports & Entertainment Appoints Corporate Finance Executive Steven Miller as Executive Vice President and Chief Financial Officer

    Steven Miller, currently Chief Financial Officer and Treasurer of Warby Parker (NYSE: WRBY), has been appointed Chief Financial Officer of Monumental Sports & Entertainment, effective October 2, 2025, and will join the Senior Executive Leadership TeamAs previously announced, after an extraordinary 25-year career at Monumental Sports & Entertainment, Peter Biché transitioned from Chief Financial Officer to Senior Advisor WASHINGTON, Sept. 9, 2025 /PRNewswire/ -- Monumental Sports & Entertainment (MSE), one of the nation's leading integrated sports, media, and entertainment companies, announced that Steven (Steve) Miller will become its Executive Vice President and Chief Financial Officer (CFO

    9/9/25 6:30:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker Announces Participation in the Goldman Sachs 32nd Annual Global Retailing Conference

    Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that the Company will be presenting at the Goldman Sachs 32nd Annual Global Retailing Conference on Thursday, September 4, 2025 at 10:20 a.m. Eastern Time. The presentation will be webcast live over the internet and can be accessed at https://investors.warbyparker.com/. An online archive will be available for a period of 90 days following the presentation. About Warby Parker Warby Parker (NYSE:WRBY) was founded in 2010 with a mission to inspire and impact the world with vision, purpose, and style–without charging a premium for it. Headquartered in New York City,

    8/28/25 4:05:00 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker Teams Up with Arch Manning for Three-Year Partnership

    The college football quarterback will support the brand's mission to inspire and impact the world with vision, purpose, and style. Warby Parker Inc. (NYSE:WRBY) (the "Company"), a lifestyle brand focused on vision for all, today announced a three-year partnership with Texas Longhorns quarterback Arch Manning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250827456069/en/ A glasses wearer since age three—and Warby Parker wearer since middle school—Manning has long depended on prescription eyewear to help him see. He embodies the company's forward-thinking mindset and belief that seeing clearly empowers people to live with conf

    8/27/25 9:00:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Gilboa David Abraham sold $1,626,081 worth of shares (58,960 units at $27.58) and converted options into 58,960 shares (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    9/19/25 5:42:06 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Co-Chief Executive Officer Blumenthal Neil Harris converted options into 8,916 shares and sold $245,368 worth of shares (8,916 units at $27.52) (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    9/19/25 5:40:24 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Co-Chief Executive Officer Gilboa David Abraham sold $1,129,831 worth of shares (41,040 units at $27.53) and converted options into 41,040 shares (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    9/15/25 5:17:50 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Singer Bradley E bought $965,750 worth of shares (75,000 units at $12.88) (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    8/14/24 4:52:02 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    SEC Filings

    View All

    SEC Form 144 filed by Warby Parker Inc.

    144 - Warby Parker Inc. (0001504776) (Subject)

    9/8/25 5:55:33 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Warby Parker Inc. (0001504776) (Filer)

    8/7/25 6:56:28 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    SEC Form SCHEDULE 13G filed by Warby Parker Inc.

    SCHEDULE 13G - Warby Parker Inc. (0001504776) (Subject)

    8/6/25 12:19:41 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Leadership Updates

    Live Leadership Updates

    View All

    Monumental Sports & Entertainment Appoints Corporate Finance Executive Steven Miller as Executive Vice President and Chief Financial Officer

    Steven Miller, currently Chief Financial Officer and Treasurer of Warby Parker (NYSE: WRBY), has been appointed Chief Financial Officer of Monumental Sports & Entertainment, effective October 2, 2025, and will join the Senior Executive Leadership TeamAs previously announced, after an extraordinary 25-year career at Monumental Sports & Entertainment, Peter Biché transitioned from Chief Financial Officer to Senior Advisor WASHINGTON, Sept. 9, 2025 /PRNewswire/ -- Monumental Sports & Entertainment (MSE), one of the nation's leading integrated sports, media, and entertainment companies, announced that Steven (Steve) Miller will become its Executive Vice President and Chief Financial Officer (CFO

    9/9/25 6:30:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker appoints Ronald A. Williams as Lead Director and welcomes Bradley E. Singer to Board of Directors

    Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company") announced today the appointment of Ron Williams as Lead Director. "Ron's deep expertise in transformational leadership is helping Warby Parker lead the way in making the optical industry more customer and patient friendly. Our shareholders and our team are lucky to have such an exceptional and experienced leader as our first Lead Director," said Neil Blumenthal, co-Founder and co-CEO. The Company has also appointed a new independent director, Brad Singer, to its board of directors. Mr. Singer's appointment is effective today, August 1, 2024. "Brad brings a wealth of experience as a dynamic operator and investor," said Dav

    8/1/24 4:15:00 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Financials

    Live finance-specific insights

    View All

    Warby Parker Announces Second Quarter 2025 Results

    Net revenue increased 14% year over year to $214 million; Raises outlook Active Customers increased 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the second quarter ended June 30, 2025. "It has been a busy and exciting year marked by major milestones. We celebrated opening our 300th store and distributing 20 million pairs of glasses to people in need around the world. Looking ahead, our partnership with Google to develop intelligent eyewear is a testament to Warby Parker's commitment to innovation as we shape the future of how people

    8/7/25 6:45:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker to Announce Second Quarter 2025 Financial Results August 7, 2025

    Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the second quarter ended June 30, 2025 will be released before market open on August 7, 2025. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 404-975-4839 from international locations. The conference passcode is 754099. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.com where present

    7/17/25 4:05:00 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker Announces First Quarter 2025 Results

    Net revenue increased 12% year over year to $224 million Active Customers increased 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the first quarter ended March 31, 2025. "Our team delivered a strong start to 2025. We opened 11 net new stores, exceeded profitability expectations, drove the highest e-commerce growth we've seen since 2021, and delivered our seventh consecutive quarter of accelerating active customer growth," shared Co-Founder and Co-CEO Neil Blumenthal. "Looking to the rest of the year, we'll leverage our diversified suppl

    5/8/25 6:45:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

    11/14/24 5:08:23 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

    11/14/24 1:30:16 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

    11/12/24 10:40:28 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care